Literature DB >> 1670759

Retinoic acid receptors in myeloid leukemia: characterization of receptors in retinoic acid-resistant K-562 cells.

K A Robertson1, L Mueller, S J Collins.   

Abstract

Although mRNA for the retinoic acid receptor alpha (RAR-alpha) is expressed in many different myeloid leukemias, most of these leukemia cells exhibit little if any phenotypic response when exposed to retinoic acid (RA). To determine whether such RA resistance is related to altered RA receptor structure or function, we performed a detailed analysis of nuclear RA receptors in RA-resistant K-562 cells. These cells exhibit RA receptors of the same approximate molecular weight and similar kd as those exhibited by the RA-sensitive HL-60 leukemia cell line, but the number of RA receptors in the RA-resistant K-562 cells (80 per cell) is significantly lower than that exhibited by RA-sensitive HL-60 cells (550 per cell). Retroviral-mediated transduction of RAR-alpha cDNA into K-562 significantly increased the number of RA receptors to 2,000 per cell. These RAR-alpha-transduced K-562 cells, when incubated with RA, exhibit diminished cell proliferation associated with decreased c-myc expression and an accumulation of cells in G0/G1. In addition, these RA-treated cells exhibit downregulation of the CD15 surface antigen and a slight increase in hemoglobin production but manifest no other evidence of significant erythroid, megakaryocytic, or myeloid differentiation. These results indicate that an elevated number of nuclear RA receptors can be involved in altering proliferation but not necessarily the differentiation of certain RA-treated myeloid leukemia cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1670759

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  5 in total

Review 1.  A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics-->mechanism(s) of interaction).

Authors:  B A Teicher
Journal:  Cancer Metastasis Rev       Date:  1996-06       Impact factor: 9.264

2.  Inhibition of the redox function of APE1/Ref-1 in myeloid leukemia cell lines results in a hypersensitive response to retinoic acid-induced differentiation and apoptosis.

Authors:  Melissa L Fishel; E Scott Colvin; Meihua Luo; Mark R Kelley; Kent A Robertson
Journal:  Exp Hematol       Date:  2010-09-06       Impact factor: 3.084

3.  The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells.

Authors:  Vivian G Oehler; Katherine A Guthrie; Carrie L Cummings; Kathleen Sabo; Brent L Wood; Ted Gooley; Taimei Yang; Mirjam T Epping; Yaping Shou; Era Pogosova-Agadjanyan; Paula Ladne; Derek L Stirewalt; Janis L Abkowitz; Jerald P Radich
Journal:  Blood       Date:  2009-07-22       Impact factor: 22.113

4.  In vivo modulation of several anticancer agents by beta-carotene.

Authors:  B A Teicher; J L Schwartz; S A Holden; G Ara; D Northey
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

5.  Induced myelomonocytic differentiation in leukemia cells is accompanied by noncanonical transcription factor expression.

Authors:  Holly A Jensen; Harmony B Yourish; Rodica P Bunaciu; Jeffrey D Varner; Andrew Yen
Journal:  FEBS Open Bio       Date:  2015-09-28       Impact factor: 2.693

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.